Dexetimide

Identification

Name
Dexetimide
Accession Number
DB08997
Type
Small Molecule
Groups
Withdrawn
Description

A muscarinic antagonist that has been used to treat neuroleptic-induced parkinsonism. Benzetimide is the (-)-enantimorph of dexetimide.

Structure
Thumb
Synonyms
Not Available
Categories
UNII
43477QYX3D
CAS number
21888-98-2
Weight
Average: 362.4647
Monoisotopic: 362.199428086
Chemical Formula
C23H26N2O2
InChI Key
LQQIVYSCPWCSSD-HSZRJFAPSA-N
InChI
InChI=1S/C23H26N2O2/c26-21-11-14-23(22(27)24-21,19-9-5-2-6-10-19)20-12-15-25(16-13-20)17-18-7-3-1-4-8-18/h1-10,20H,11-17H2,(H,24,26,27)/t23-/m1/s1
IUPAC Name
(3S)-3-(1-benzylpiperidin-4-yl)-6-hydroxy-3-phenyl-2,3,4,5-tetrahydropyridin-2-one
SMILES
OC1=NC(=O)[[email protected]@](CC1)(C1CCN(CC2=CC=CC=C2)CC1)C1=CC=CC=C1

Pharmacology

Indication
Not Available
Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
1,10-PhenanthrolineThe therapeutic efficacy of Dexetimide can be decreased when used in combination with 1,10-Phenanthroline.Experimental
AclidiniumAclidinium may increase the anticholinergic activities of Dexetimide.Approved
AlcuroniumThe risk or severity of adverse effects can be increased when Dexetimide is combined with Alcuronium.Experimental
AlfentanilThe risk or severity of adverse effects can be increased when Dexetimide is combined with Alfentanil.Approved, Illicit
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Dexetimide is combined with Alphacetylmethadol.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Dexetimide is combined with Alphaprodine.Illicit
AmbenoniumThe therapeutic efficacy of Dexetimide can be decreased when used in combination with Ambenonium.Approved
Anisotropine MethylbromideThe risk or severity of adverse effects can be increased when Dexetimide is combined with Anisotropine Methylbromide.Approved
AtracuriumThe risk or severity of adverse effects can be increased when Dexetimide is combined with Atracurium.Experimental
Atracurium besylateThe risk or severity of adverse effects can be increased when Dexetimide is combined with Atracurium besylate.Approved
AtropineThe risk or severity of adverse effects can be increased when Atropine is combined with Dexetimide.Approved, Vet Approved
BenactyzineThe risk or severity of adverse effects can be increased when Dexetimide is combined with Benactyzine.Withdrawn
BendroflumethiazideThe serum concentration of Bendroflumethiazide can be increased when it is combined with Dexetimide.Approved
BenzatropineThe risk or severity of adverse effects can be increased when Benzatropine is combined with Dexetimide.Approved
BezitramideThe risk or severity of adverse effects can be increased when Dexetimide is combined with Bezitramide.Experimental, Illicit, Withdrawn
BiperidenThe risk or severity of adverse effects can be increased when Biperiden is combined with Dexetimide.Approved
BornaprineThe risk or severity of adverse effects can be increased when Dexetimide is combined with Bornaprine.Experimental
Botulinum Toxin Type ADexetimide may increase the anticholinergic activities of Botulinum Toxin Type A.Approved, Investigational
Botulinum Toxin Type BDexetimide may increase the anticholinergic activities of Botulinum Toxin Type B.Approved
BuprenorphineThe risk or severity of adverse effects can be increased when Dexetimide is combined with Buprenorphine.Approved, Illicit, Investigational, Vet Approved
ButorphanolThe risk or severity of adverse effects can be increased when Dexetimide is combined with Butorphanol.Approved, Illicit, Vet Approved
CarfentanilThe risk or severity of adverse effects can be increased when Dexetimide is combined with Carfentanil.Illicit, Vet Approved
ChlorothiazideThe serum concentration of Chlorothiazide can be increased when it is combined with Dexetimide.Approved, Vet Approved
ChlorphenoxamineThe risk or severity of adverse effects can be increased when Dexetimide is combined with Chlorphenoxamine.Withdrawn
ChlorthalidoneThe serum concentration of Chlorthalidone can be increased when it is combined with Dexetimide.Approved
CimetropiumDexetimide may increase the anticholinergic activities of Cimetropium.Experimental
CodeineThe risk or severity of adverse effects can be increased when Dexetimide is combined with Codeine.Approved, Illicit
CoumaphosThe therapeutic efficacy of Dexetimide can be decreased when used in combination with Coumaphos.Vet Approved
CyclopenthiazideThe serum concentration of Cyclopenthiazide can be increased when it is combined with Dexetimide.Experimental
CyclopentolateThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Dexetimide.Approved
DarifenacinThe risk or severity of adverse effects can be increased when Dexetimide is combined with Darifenacin.Approved, Investigational
DecamethoniumThe therapeutic efficacy of Dexetimide can be decreased when used in combination with Decamethonium.Approved
DemecariumThe therapeutic efficacy of Dexetimide can be decreased when used in combination with Demecarium.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Dexetimide is combined with Desloratadine.Approved, Investigational
DextromoramideThe risk or severity of adverse effects can be increased when Dexetimide is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dexetimide is combined with Dextropropoxyphene.Approved, Illicit, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dexetimide is combined with Dezocine.Approved
DichlorvosThe therapeutic efficacy of Dexetimide can be decreased when used in combination with Dichlorvos.Vet Approved
DicyclomineThe risk or severity of adverse effects can be increased when Dexetimide is combined with Dicyclomine.Approved
DihydrocodeineThe risk or severity of adverse effects can be increased when Dexetimide is combined with Dihydrocodeine.Approved, Illicit
DihydroetorphineThe risk or severity of adverse effects can be increased when Dexetimide is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dexetimide is combined with Dihydromorphine.Experimental, Illicit
DiphenoxylateThe risk or severity of adverse effects can be increased when Dexetimide is combined with Diphenoxylate.Approved, Illicit
DistigmineThe therapeutic efficacy of Dexetimide can be decreased when used in combination with Distigmine.Experimental
DonepezilThe therapeutic efficacy of Dexetimide can be decreased when used in combination with Donepezil.Approved
DPDPEThe risk or severity of adverse effects can be increased when Dexetimide is combined with DPDPE.Investigational
DronabinolDexetimide may increase the tachycardic activities of Dronabinol.Approved, Illicit
EchothiophateThe therapeutic efficacy of Dexetimide can be decreased when used in combination with Echothiophate.Approved
EdrophoniumThe therapeutic efficacy of Dexetimide can be decreased when used in combination with Edrophonium.Approved
EluxadolineDexetimide may increase the constipating activities of Eluxadoline.Approved
EmeproniumThe risk or severity of adverse effects can be increased when Dexetimide is combined with Emepronium.Experimental
EtanautineThe risk or severity of adverse effects can be increased when Dexetimide is combined with Etanautine.Experimental
EthopropazineThe risk or severity of adverse effects can be increased when Ethopropazine is combined with Dexetimide.Approved
EthylmorphineThe risk or severity of adverse effects can be increased when Dexetimide is combined with Ethylmorphine.Approved, Illicit
EtorphineThe risk or severity of adverse effects can be increased when Dexetimide is combined with Etorphine.Illicit, Vet Approved
EtybenzatropineThe risk or severity of adverse effects can be increased when Dexetimide is combined with Etybenzatropine.Experimental
FentanylThe risk or severity of adverse effects can be increased when Dexetimide is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FenthionThe therapeutic efficacy of Dexetimide can be decreased when used in combination with Fenthion.Vet Approved
FesoterodineThe risk or severity of adverse effects can be increased when Dexetimide is combined with Fesoterodine.Approved
GalantamineThe therapeutic efficacy of Dexetimide can be decreased when used in combination with Galantamine.Approved
GallamineThe risk or severity of adverse effects can be increased when Dexetimide is combined with Gallamine.Experimental
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Dexetimide is combined with Gallamine Triethiodide.Approved
Ginkgo bilobaThe therapeutic efficacy of Dexetimide can be decreased when used in combination with Ginkgo biloba.Approved, Nutraceutical
Glucagon recombinantThe risk or severity of adverse effects can be increased when Dexetimide is combined with Glucagon recombinant.Approved
GlycopyrroniumDexetimide may increase the anticholinergic activities of Glycopyrronium.Approved, Investigational, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Dexetimide is combined with Heroin.Approved, Illicit
HexamethoniumThe risk or severity of adverse effects can be increased when Dexetimide is combined with Hexamethonium.Experimental
HomatropineThe risk or severity of adverse effects can be increased when Dexetimide is combined with Homatropine.Approved
Huperzine AThe therapeutic efficacy of Dexetimide can be decreased when used in combination with Huperzine A.Investigational
HydrochlorothiazideThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Dexetimide.Approved, Vet Approved
HydrocodoneThe risk or severity of adverse effects can be increased when Dexetimide is combined with Hydrocodone.Approved, Illicit
HydroflumethiazideThe serum concentration of Hydroflumethiazide can be increased when it is combined with Dexetimide.Approved
HydromorphoneThe risk or severity of adverse effects can be increased when Dexetimide is combined with Hydromorphone.Approved, Illicit
HyoscyamineThe risk or severity of adverse effects can be increased when Dexetimide is combined with Hyoscyamine.Approved
IndapamideThe serum concentration of Indapamide can be increased when it is combined with Dexetimide.Approved
IpidacrineThe therapeutic efficacy of Dexetimide can be decreased when used in combination with Ipidacrine.Experimental
Ipratropium bromideThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Dexetimide.Approved
IsoflurophateThe therapeutic efficacy of Dexetimide can be decreased when used in combination with Isoflurophate.Approved, Withdrawn
ItoprideThe therapeutic efficacy of Itopride can be decreased when used in combination with Dexetimide.Investigational
KetobemidoneThe risk or severity of adverse effects can be increased when Dexetimide is combined with Ketobemidone.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Dexetimide is combined with Levomethadyl Acetate.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Dexetimide is combined with Levorphanol.Approved
LofentanilThe risk or severity of adverse effects can be increased when Dexetimide is combined with Lofentanil.Illicit
MalathionThe therapeutic efficacy of Dexetimide can be decreased when used in combination with Malathion.Approved, Investigational
MazaticolThe risk or severity of adverse effects can be increased when Dexetimide is combined with Mazaticol.Experimental
MecamylamineThe risk or severity of adverse effects can be increased when Dexetimide is combined with Mecamylamine.Approved
MefloquineThe therapeutic efficacy of Dexetimide can be decreased when used in combination with Mefloquine.Approved
MemantineThe therapeutic efficacy of Dexetimide can be decreased when used in combination with Memantine.Approved, Investigational
MeptazinolThe risk or severity of adverse effects can be increased when Dexetimide is combined with Meptazinol.Experimental
MethadoneThe risk or severity of adverse effects can be increased when Dexetimide is combined with Methadone.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Dexetimide is combined with Methadyl Acetate.Approved, Illicit
Methanesulfonyl FluorideThe therapeutic efficacy of Dexetimide can be decreased when used in combination with Methanesulfonyl Fluoride.Investigational
MethanthelineThe risk or severity of adverse effects can be increased when Dexetimide is combined with Methantheline.Approved
MethyclothiazideThe serum concentration of Methyclothiazide can be increased when it is combined with Dexetimide.Approved
Methyl salicylateThe therapeutic efficacy of Dexetimide can be decreased when used in combination with Methyl salicylate.Approved, Vet Approved
MetixeneThe risk or severity of adverse effects can be increased when Dexetimide is combined with Metixene.Approved
MetoclopramideThe therapeutic efficacy of Dexetimide can be decreased when used in combination with Metoclopramide.Approved, Investigational
MetolazoneThe serum concentration of Metolazone can be increased when it is combined with Dexetimide.Approved
MianserinMianserin may increase the anticholinergic activities of Dexetimide.Approved
MinaprineThe therapeutic efficacy of Dexetimide can be decreased when used in combination with Minaprine.Approved
MirabegronThe risk or severity of adverse effects can be increased when Dexetimide is combined with Mirabegron.Approved
MorphineThe risk or severity of adverse effects can be increased when Dexetimide is combined with Morphine.Approved, Investigational
NabiloneDexetimide may increase the tachycardic activities of Nabilone.Approved, Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Dexetimide is combined with Nalbuphine.Approved
NeostigmineThe therapeutic efficacy of Dexetimide can be decreased when used in combination with Neostigmine.Approved, Vet Approved
NicomorphineThe risk or severity of adverse effects can be increased when Dexetimide is combined with Nicomorphine.Experimental
NormethadoneThe risk or severity of adverse effects can be increased when Dexetimide is combined with Normethadone.Approved, Illicit
OpiumThe risk or severity of adverse effects can be increased when Dexetimide is combined with Opium.Approved, Illicit
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Dexetimide.Approved
OtiloniumThe risk or severity of adverse effects can be increased when Dexetimide is combined with Otilonium.Experimental
OxitropiumThe risk or severity of adverse effects can be increased when Dexetimide is combined with Oxitropium.Investigational
OxybutyninThe risk or severity of adverse effects can be increased when Dexetimide is combined with Oxybutynin.Approved, Investigational
OxycodoneThe risk or severity of adverse effects can be increased when Dexetimide is combined with Oxycodone.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Dexetimide is combined with Oxymorphone.Approved, Investigational, Vet Approved
OxyphenoniumThe risk or severity of adverse effects can be increased when Dexetimide is combined with Oxyphenonium.Approved
PancuroniumThe risk or severity of adverse effects can be increased when Dexetimide is combined with Pancuronium.Approved
ParaoxonThe therapeutic efficacy of Dexetimide can be decreased when used in combination with Paraoxon.Experimental
PentazocineThe risk or severity of adverse effects can be increased when Dexetimide is combined with Pentazocine.Approved, Vet Approved
PentoliniumThe risk or severity of adverse effects can be increased when Dexetimide is combined with Pentolinium.Approved
PethidineThe risk or severity of adverse effects can be increased when Dexetimide is combined with Pethidine.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Dexetimide is combined with Phenazocine.Experimental
PhenglutarimideThe risk or severity of adverse effects can be increased when Dexetimide is combined with Phenglutarimide.Experimental
PhenoperidineThe risk or severity of adverse effects can be increased when Dexetimide is combined with Phenoperidine.Experimental
PhysostigmineThe therapeutic efficacy of Dexetimide can be decreased when used in combination with Physostigmine.Approved
PipecuroniumThe risk or severity of adverse effects can be increased when Dexetimide is combined with Pipecuronium.Approved
PirenzepineThe risk or severity of adverse effects can be increased when Dexetimide is combined with Pirenzepine.Approved
PiritramideThe risk or severity of adverse effects can be increased when Dexetimide is combined with Piritramide.Investigational
PolythiazideThe serum concentration of Polythiazide can be increased when it is combined with Dexetimide.Approved
Potassium ChlorideDexetimide may increase the ulcerogenic activities of Potassium Chloride.Approved, Withdrawn
PramlintidePramlintide may increase the anticholinergic activities of Dexetimide.Approved, Investigational
ProcyclidineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Dexetimide.Approved
PropanthelineThe risk or severity of adverse effects can be increased when Dexetimide is combined with Propantheline.Approved
PropiverineThe risk or severity of adverse effects can be increased when Dexetimide is combined with Propiverine.Investigational
PyridostigmineThe therapeutic efficacy of Dexetimide can be decreased when used in combination with Pyridostigmine.Approved
QuinethazoneThe serum concentration of Quinethazone can be increased when it is combined with Dexetimide.Approved
QuinidineThe risk or severity of adverse effects can be increased when Dexetimide is combined with Quinidine.Approved
RamosetronDexetimide may increase the constipating activities of Ramosetron.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Dexetimide is combined with Remifentanil.Approved
RivastigmineThe therapeutic efficacy of Dexetimide can be decreased when used in combination with Rivastigmine.Approved, Investigational
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Dexetimide.Approved
Scopolamine butylbromideThe risk or severity of adverse effects can be increased when Dexetimide is combined with Scopolamine butylbromide.Approved, Vet Approved
SecretinThe therapeutic efficacy of Secretin can be decreased when used in combination with Dexetimide.Approved, Investigational
SolifenacinThe risk or severity of adverse effects can be increased when Dexetimide is combined with Solifenacin.Approved
SufentanilThe risk or severity of adverse effects can be increased when Dexetimide is combined with Sufentanil.Approved, Investigational
SulpirideThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Dexetimide.Approved
TacrineThe therapeutic efficacy of Dexetimide can be decreased when used in combination with Tacrine.Withdrawn
TapentadolThe risk or severity of adverse effects can be increased when Dexetimide is combined with Tapentadol.Approved
TilidineThe risk or severity of adverse effects can be increased when Dexetimide is combined with Tilidine.Experimental
TiotropiumDexetimide may increase the anticholinergic activities of Tiotropium.Approved
TolterodineThe risk or severity of adverse effects can be increased when Dexetimide is combined with Tolterodine.Approved, Investigational
TopiramateThe risk or severity of adverse effects can be increased when Dexetimide is combined with Topiramate.Approved
TramadolThe risk or severity of adverse effects can be increased when Dexetimide is combined with Tramadol.Approved, Investigational
TrichlorfonThe therapeutic efficacy of Dexetimide can be decreased when used in combination with Trichlorfon.Vet Approved
TrichlormethiazideThe serum concentration of Trichlormethiazide can be increased when it is combined with Dexetimide.Approved, Vet Approved
TrihexyphenidylThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Dexetimide.Approved
TrimethaphanThe risk or severity of adverse effects can be increased when Dexetimide is combined with Trimethaphan.Approved
TropatepineThe risk or severity of adverse effects can be increased when Dexetimide is combined with Tropatepine.Experimental
TropicamideThe risk or severity of adverse effects can be increased when Tropicamide is combined with Dexetimide.Approved
TrospiumThe risk or severity of adverse effects can be increased when Dexetimide is combined with Trospium.Approved
TubocurarineThe risk or severity of adverse effects can be increased when Dexetimide is combined with Tubocurarine.Approved
UmeclidiniumUmeclidinium may increase the anticholinergic activities of Dexetimide.Approved
VecuroniumThe risk or severity of adverse effects can be increased when Dexetimide is combined with Vecuronium.Approved
Food Interactions
Not Available

References

Synthesis Reference

U.S. Patent 3,125,578.

General References
Not Available
External Links
ChemSpider
28615
ChEBI
135531
ChEMBL
CHEMBL1908364
ATC Codes
N04AA08 — Dexetimide
AHFS Codes
Not Available
PDB Entries
Not Available
FDA label
Not Available
MSDS
Not Available

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)299-301.5U.S. Patent 3,125,578.
Predicted Properties
PropertyValueSource
Water Solubility0.00505 mg/mLALOGPS
logP3.75ALOGPS
logP2.85ChemAxon
logS-4.9ALOGPS
pKa (Strongest Acidic)7.67ChemAxon
pKa (Strongest Basic)8.43ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area52.9 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity106.66 m3·mol-1ChemAxon
Polarizability40.55 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of chemical entities known as n-benzylpiperidines. These are heterocyclic Compounds containing a piperidine ring conjugated to a benzyl group through one nitrogen ring atom.
Kingdom
Chemical entities
Super Class
Organic compounds
Class
Organoheterocyclic compounds
Sub Class
Piperidines
Direct Parent
N-benzylpiperidines
Alternative Parents
Phenylmethylamines / Benzylamines / Tetrahydropyridines / Aralkylamines / Trialkylamines / N-acylimines / Lactims / Amino acids and derivatives / Propargyl-type 1,3-dipolar organic compounds / Azacyclic compounds
show 4 more
Substituents
N-benzylpiperidine / Benzylamine / Phenylmethylamine / Aralkylamine / Tetrahydropyridine / Monocyclic benzene moiety / Hydropyridine / Benzenoid / Amino acid or derivatives / Tertiary amine
show 17 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
Not Available

Drug created on June 16, 2014 13:39 / Updated on October 02, 2017 06:12